Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Rural Cameroon study indicates need to double HIV treatment success, monitor outcomes in west, central Africa to control epidemic
Researchers cite critical need for stronger capacities in remote areas to find treatment resistance, failure The numbers of people who are receiving antiretroviral treatment HIV in remote […]
The following is a guest post by Emily Demotte Lisinopril 20 mg by mouth at eight AM? Check. Having already verified the patient’s identification, I scanned […]
Last June, a Perspective piece in the New England Journal of Medicine noted the critical place that the World Health Organization’s list of Essential Medicines had […]
Trump administration should be ready for global infectious disease outbreaks from day one, panel says
No matter how hard the Trump administration will try to focus solely on domestic issues to “make America great again,” Bill Steiger said last week at […]